Equillium (EQ) Non Operating Income (2018 - 2024)
Equillium (EQ) posted quarterly Non Operating Income of $57000.0 for Q1 2024, down 75.0% year-over-year from $228000.0 in Q2 2023, and down 75.0% quarter-over-quarter from $228000.0 in Q1 2023.
Equillium (EQ) Non Operating Income (2018 - 2024) Analysis & Trends
Equillium (EQ) has reported Non Operating Income for 7 consecutive years, with $57000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Non Operating Income fell 75.0% year-over-year to $57000.0; the TTM figure through Mar 2024 stood at $598000.0 (up 1761.11% YoY), while the FY2023 annual figure was $1.8 million, up 601.99% from the prior year.
- Non Operating Income declined to $57000.0 in Q1 2024 per EQ's latest filing, from $228000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $731000.0 in Q4 2022 and bottomed at -$577000.0 in Q2 2022.
- Historically, Non Operating Income has averaged -$114142.9 across 5 years, with a median of -$161000.0 in 2021.
- Annual changes were most pronounced in 2021 — Non Operating Income tumbled 550.0% — and 2022, when it jumped 412.39%.
- Equillium's Non Operating Income stood at $52000.0 in 2020, then sank by 550.0% to -$234000.0 in 2021, then surged by 412.39% to $731000.0 in 2022, then plunged by 68.81% to $228000.0 in 2023, then slumped by 75.0% to $57000.0 in 2024.
- Business Quant data shows EQ's Non Operating Income at $57000.0 in Q1 2024, $228000.0 in Q1 2023, and $731000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 57,000.00 |
| Mar 31, 2023 | 228,000.00 |
| Dec 31, 2022 | 731,000.00 |
| Sep 30, 2022 | -418,000.00 |
| Jun 30, 2022 | -577,000.00 |
| Mar 31, 2022 | -88,000.00 |
| Dec 31, 2021 | -234,000.00 |
| Sep 30, 2021 | -421,000.00 |
| Jun 30, 2021 | -315,000.00 |
| Mar 31, 2021 | -296,000.00 |
| Dec 31, 2020 | 52,000.00 |
| Sep 30, 2020 | -81,000.00 |
| Jun 30, 2020 | 149,000.00 |
| Mar 31, 2020 | -385,000.00 |
| Dec 31, 2019 | 49,000.00 |
| Sep 30, 2019 | 310,000.00 |
| Jun 30, 2019 | 370,000.00 |
| Mar 31, 2019 | 398,000.00 |
| Dec 31, 2018 | -764,000.00 |
| Sep 30, 2018 | -2.69 Mn |